Orthocell's 92 US Units in October Show Slow Medtech Climb

Orthocell Limited said on November 1, 2026 that it sold 92 units of its Remplir nerve repair product in the United States in October 2026, generating AU$279,000 in revenue and an 84% increase over the average of 50 units a month in the first quarter of its 2027 fiscal year, according to a company statement distributed by PR Newswire.

The figures are worth reading carefully rather than celebrating. A record month that totals fewer than 100 units and well under AU$300,000 in revenue says less about demand than about how long it takes a device company to turn regulatory clearance into purchase orders. Orthocell holds approvals in seven international jurisdictions and says it has manufacturing capacity in place, yet US volume still depends on surgeons trying the product and on hospital Value Assessment Committee approvals clearing the way.

That is the real lesson for founders selling into American hospitals: approval is the beginning of the sales cycle, not the end of it. Chief executive and managing director Paul Anderson said establishing a new medical technology in a large market "takes time and sustained effort." Chairman John Van Der Wielen said the company is expanding manufacturing capacity in anticipation of higher demand — spending that has to be funded through quarters when adoption curves are measured in dozens of units.

This story was first reported by PR Newswire.